TGFB1 and systemic sclerosis: Although there is a limited number of studies associating ILC2s in the pathogenesis of SSc, we believe that findings implicating TGF-β in their potential fibrotic mechanism might be promising in utilizing alternative therapeutic strategies that are based on TGF-β blocking.